Magnetic resonance imaging and magnetic resonance spectroscopy in dementias. J Geriatr Psychiatry Neurol 2001; 14: 145–66., , , .
Magnetic resonance imaging and spectroscopy in Parkinson's disease. Adv Neurol 2001; 86: 197–203..
Neuroimaging findings in human prion disease. J Neurol Neurosurg Psychiatry 2007; 78: 664–70., , , , .
Neuroimaging in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2003; 4: 243–8., .
MR spectroscopy in neurodegenerative disease. Mol Imaging Biol 2007; 9: 196–203..
Current definition and classification of dementia diseases. Acta Neurol Scand 1996; 168(suppl): 39–44..
Accuracy of four clinical diagnostic criteria for the diagnosis of neurodegenerative dementias. Neurology 1999; 53: 1292–9., , , , , , et al.
A clinicopathological comparison of community-based and clinic-based cohorts of patients with dementia. Arch Neurol 1999; 56: 1368–73., , , , , , et al.
1H magnetic resonance spectroscopy in dementia. Br J Radiol 2007: 80(Spec No 2): S146–52..
Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline. Eur J Neurol 2007; 14: e1–26., , , , , , et al.
Early identification of cognitive deficits: Preclinical Alzheimer's disease and mild cognitive impairment. Geriatrics 2007; 62: 19–23., , .
Preclinical Alzheimer disease: Neuropsychological test performance 1.5 to 8 years prior to onset. Neurology 2004; 63: 2341–7., , , , , , et al.
Complex activities of daily living in mild cognitive impairment: Conceptual and diagnostic issues. Age Ageing 2006; 35: 240–5., , , , , , et al.
Clinical features of Alzheimer's disease. Eur Arch Psychiatry Clin Neurosci 1999; 249: 288–90., .
Abnormalities of neural circuitry in Alzheimer's disease: Hippocampus and cortical cholinergic innervation. Neurology 1998; 51: S18–S29..
“Preclinical” AD revisited: Neuropathology of cognitively normal older adults. Neurology 2000; 55: 370–6., , , , , .
Loss and atrophy of layer II entorhinal cortex neurons in elderly people with mild cognitive impairment. Ann Neurol 2001; 49: 202–13., , , , , , et al.
Quantitative magnetic resonance techniques as surrogate markers of Alzheimer's disease. Neurorx 2004; 1: 196–205., , Jr.
Automatic volumetry on MR brain images can support diagnostic decision making. BMC Med Imaging 2008; 8: 9., , , , , .
Automatic classification of MR scans in Alzheimer's disease. Brain 2008; 131: 681–9., , , , , , et al.
Imaging of onset and progression of Alzheimer's disease with voxel-compression mapping of serial magnetic resonance images. Lancet 2001; 358: 201–05., , , , , .
A voxel based morphometry study on mild cognitive impairment. J Neurol Neurosurg Psychiatry 2005; 76: 11–14., , , , , , et al.
Computer-assisted imaging to assess brain structure in healthy and diseased brains. Lancet Neurol 2003; 2: 79–88., , , , , .
Probable Alzheimer disease: Diagnosis with proton MR spectroscopy. Radiology 1995; 195: 65–72., , , , , , et al.
Cortical and subcortical chemical pathology in Alzheimer's disease as assessed by multislice proton magnetic resonance spectroscopic imaging. Neurology 1996: 47: 696–704., , , , , , et al.
Prediction of cognitive decline in early Alzheimer's disease [Letter]. Lancet 1998; 352: 1678., , .
Selective reduction of N-acetylaspartate in medial temporal and parietal lobes in AD. Neurology 2002; 58: 928–35., , , , , , et al.
1H MR spectroscopy in common dementias. Neurology 2004; 63: 1393–8., , , , , , et al.
Brain proton spectroscopy in dementia: An aid to clinical diagnosis [Letter]. Lancet 1999; 353: 1063–4., , , , .
A review of 1H MR spectroscopy findings in Alzheimer's disease. Neuroimaging Clin N Am 2005; 15: 847–52, xi., , .
Magnetic resonance spectroscopy in AD. Neurology 2001; 56: 592–8., .
Alzheimer disease and subcortical ischemic vascular dementia: Evaluation by combining MR imaging segmentation and H-1 MR spectroscopic imaging. Radiology 1996; 198: 537–45., , , , , , et al.
Changes of hippocampal N-acetyl aspartate and volume in Alzheimer's disease. A proton MR spectroscopic imaging and MRI study. Neurology 1997; 49: 1513–21., , , , , , et al.
N-Acetylaspartate in the CNS: From neurodiagnostics to neurobiology. Prog Neurobiol 2007; 81: 89–131., , , , .
An in vitro 1H nuclear magnetic resonance study of the temporoparietal cortex of Alzheimer brains. Exp Brain Res 1995; 102: 503–10., , , , , , et al.
Psychosis in Alzheimer disease: Postmortem magnetic resonance spectroscopy evidence of excess neuronal and membrane phospholipid pathology. Neurobiol Aging 2002; 23: 547–53., , , , , , et al.
Alzheimer disease: Depiction of increased cerebral myo-inositol with proton MR spectroscopy. Radiology 1993; 187: 433–7., , , , , .
In vivo MR spectroscopy of human dementia. Neuroimaging Clin N Am 1998; 8: 809–22., , , , , .
Similar 1H magnetic resonance spectroscopic metabolic pattern in the medial temporal lobes of patients with mild cognitive impairment and Alzheimer disease. Brain Res 2004; 1003: 26–35., , , , .
Differences in the metabolism of inositol and phosphoinositides by cultured cells of neuronal and glial origin. Biochim Biophys Acta 1989; 1004: 169–79., , , , .
Regional metabolic patterns in mild cognitive impairment and Alzheimer's disease: A 1H MRS study. Neurology 2000; 55: 210–7., , Jr., , , , , et al.
MRS shows abnormalities before symptoms in familial Alzheimer disease. Neurology 2006; 66: 718–22., , , , , , et al.
MR spectroscopy of brain white matter in the prediction of dementia. Neurology 2006; 66: 540–4., , , , , , et al.
In vivo magnetic resonance spectroscopy of human brain: The biophysical basis of dementia. Biophys Chem 1997; 68: 161–72., , , , , .
Correlation of regional proton magnetic resonance spectroscopic metabolic changes with cognitive deficits in mild Alzheimer disease. Arch Neurol 2002; 59: 955–62., , , , .
1H magnetic resonance spectroscopy, cognitive function, and apolipoprotein E genotype in normal aging, mild cognitive impairment and Alzheimer's disease. J Int Neuropsychol Soc 2002; 8: 934–42., , , , , , et al.
Alzheimer disease: postmortem neuropathologic correlates of antemortem 1H MR spectroscopy metabolite measurements. Radiology 2008; 248: 210–20., , , , , , et al.
Longitudinal 1H MRS changes in mild cognitive impairment and Alzheimer's disease. Neurobiol Aging 2007; 28: 1330–9., , , , , , et al.
Conversion from mild cognitive impairment to probable Alzheimer's disease predicted by brain magnetic resonance spectroscopy. Am J Psychiatry 2005; 162: 667–75., , .
Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease. Am J Psychiatry 2003; 160: 2003–11., , , , , , et al.
Treatment monitoring and response prediction with proton MR spectroscopy in AD. Neurology 2006; 67: 528–30., , , , , .
Quantitative 1H spectroscopic imaging of human brain at 4.1 T using image segmentation. Magn Reson Med 1996; 36: 21–9., , , , , , et al.
Region and tissue differences of metabolites in normally aged brain using multislice 1H magnetic resonance spectroscopic imaging. Magn Reson Med 2001; 45: 899–907., , , , , , et al.
Practice parameter: Diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001; 56: 1143–53., , , , , , et al.
Current and future uses of neuroimaging for cognitively impaired patients. Lancet Neurol 2008; 7: 161–72., , , , , , et al.
Vascular cognitive impairment: Current concepts and clinical developments. Lancet Neurol 2008; 7: 246–55., .
Clinical diagnosis of vascular dementia. J Neurol Sci 2007; 257: 44–8., , , , , , et al.
Comparison of different diagnostic criteria for vascular dementia (ADDTC, DSM-IV, ICD-10, NINDS-AIREN). Stroke 1996; 27: 30–6., , .
Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer's Disease Diagnostic and Treatment Centers. Neurology 1992; 42: 473–80., , , , , .
Vascular dementia: Diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993; 43: 250–60., , , , , , et al.
Validity of current clinical criteria for Alzheimer's disease, vascular dementia and dementia with Lewy bodies. Br J Psychiatry 1999; 174: 45–50., , , .
Multicenter clinicopathological correlation in dementia. Am J Psychiatry 1995; 152: 1476–84., , , .
Subcortical ischemic vascular dementia. Neurol Clin 2007; 25: 717–40, vi..
MRI and CT in the diagnosis of vascular dementia. J Neurol Sci 2004; 226: 9–12., , .
Neuroradiological findings in vascular dementia. Neuroradiology 2007; 49: 1–22., , , , , , et al.
Role of functional brain imaging in the evaluation of vascular dementia. Alzheimer Dis Assoc Disord 1999; 13(Suppl 3): S91–101., , , , , .
Quantitative magnetic resonance imaging differences between Alzheimer disease with and without subcortical lacunes. Alzheimer Dis Assoc Disord 2002; 16: 58–64., , , , , , et al.
The significance of cerebral white matter abnormalities 100 years after Binswanger's report. A review. Stroke 1995; 26: 1293–301., .
Clinical significance of MRI white matter lesions in the elderly. Neurology 1989; 39: 1470–4., , , , , , et al.
White matter lesions in the elderly. [Review]. J Neurol Sci 1992; 110: 1–7., , .
Magnetic resonance imaging white matter hyperintensities in clinically normal elderly individuals. Correlations with plasma concentrations of naturally occurring antioxidants. Stroke 1996; 27: 2043–7., , , , .
Neuroimaging of white matter in aging and dementia. Clin Neuropsychol 2007; 21: 73–109., , , .
Diffusion MRI studies in vascular cognitive impairment and dementia. Rev Bras Psiquiatr 2003; 25: 188–91., , .
Regional differences in diffusion abnormality in cerebral white matter lesions in patients with vascular dementia of the Binswanger type and Alzheimer's disease. Eur J Neurol 1999; 6: 195–203., , , , , , et al.
Proton magnetic resonance spectroscopy of vascular- and Alzheimer-type dementia. Arch Neuro 1996; 53: 678–80., , , , .
Regional gray and white matter metabolite differences in subjects with AD, with subcortical ischemic vascular dementia, and elderly controls with 1H magnetic resonance spectroscopic imaging. Arch Neurol 1996; 53: 167–74., , , , , .
Altered white and gray matter metabolism in CADASIL: A proton MR spectroscopy and 1H-MRSI study. Neurology 2001; 56: 635–42., , , , , .
Clinical and pathological diagnosis of frontotemporal dementia: Report of the Work Group on Frontotemporal Dementia and Pick's Disease. Arch Neurol 2001; 58: 1803–09., , , , , .
Clinical features of frontotemporal dementia. Alzheimer Dis Assoc Disord 2005; 19(Suppl 1): S3–6., .
Frontotemporal dementia. Curr Opin Neurol 2006; 19: 565–71., , .
Patterns of brain atrophy in frontotemporal dementia and semantic dementia. Neurology 2002; 58: 198–208., , , , , , et al.
Patterns of cerebral atrophy in primary progressive aphasia. Am J Geriatr Psychiatry 2002; 10: 89–97., , , , , .
Frontotemporal lobar degeneration without lobar atrophy. Arch Neurol 2006; 63: 1632–8., , , , .
Voxel-based morphometry in frontotemporal lobar degeneration with ubiquitin-positive inclusions with and without progranulin mutations. Arch Neurol 2007; 64: 371–6., , Jr., , , , , et al.
Distinct MRI atrophy patterns in autopsy-proven Alzheimer's disease and frontotemporal lobar degeneration. Am J Alzheimers Dis Other Demen 2007; 22: 474–88., , , , , , et al.
Proton magnetic resonance spectroscopy in frontotemporal dementia. J Neurol 2006; 253: 861–8., , , , , , et al.
Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the Consortium on DLB International Workshop. J Alzheimers Dis 2006; 9: 417–23..
Clinical and neuropathological correlates of dementia with Lewy bodies. Ann NY Acad Sci 2000; 920: 9–15., , , .
Clinicopathologic correlates in temporal cortex in dementia with Lewy bodies. Neurology 1999; 53: 2003–09., , , , , , et al.
Dementia with Lewy bodies. Lancet Neurol 2004; 3: 19–28., , , , , , et al.
How to diagnose dementia with Lewy bodies: State of the art. Mov Disord 2005; 20(Suppl 12): S11–20., , , .
Focal atrophy in dementia with Lewy bodies on MRI: A distinct pattern from Alzheimer's disease. Brain 2007; 130: 708–19., , , , , , et al.
Patterns of cerebral atrophy in dementia with Lewy bodies using voxel-based morphometry. Neuroimage 2002; 17: 618–30., , , , , , et al.
Parkinson's disease: Clinical features and diagnosis. J Neurol Neurosurg Psychiatry 2008; 79: 368–76..
Dopamine neuron systems in the brain: An update. Trends Neurosci 2007; 30: 194–202., .
Dopaminergic loss and inclusion body formation in alpha-synuclein mice: Implications for neurodegenerative disorders. Science 2000; 287: 1265–9., , , , , , et al.
Iron in the Parkinsonian substantia nigra. Mov Disord 1997; 12: 258–60., , , , , , et al.
alpha-synuclein promotes mitochondrial deficit and oxidative stress. Am J Pathol 2000; 157: 401–10., , , , , , et al.
The pathogenesis of cell death in Parkinson's disease. Neurology 2006; 66: S24–S36., .
The diagnosis of Parkinson's disease. Lancet Neurol 2006; 5: 75–86., , .
Treatment options for Parkinson's disease. Curr Opin Neurol 2002; 15: 467–76., .
Deep brain stimulation for Parkinson's disease. Neurotherapeutics 2008; 5: 309–19., .
Does this patient have Parkinson disease? J Am Med Assoc 2003; 289: 347–53., , , , , , et al.
The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 2002; 125: 861–70., , , .
Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord 2003; 18: 467–86., , , , , , et al.
An update on conventional and advanced magnetic resonance imaging techniques in the differential diagnosis of neurodegenerative parkinsonism. Curr Opin Neurol 2005; 18: 370–5., .
Differential diagnosis of Parkinson's disease and atypical parkinsonian disorders by magnetic resonance imaging. Neurol Sci 2003; 24(Suppl 1): S35–7..
Voxel-based morphometry detects cortical atrophy in the Parkinson variant of multiple system atrophy. Mov Disord 2003; 18: 1132–8., , , , , , et al.
Comparison of magnetic resonance imaging in subtypes of multiple system atrophy. Parkinsonism Relat Disord 2004; 10: 363–8., , , .
How to diagnose MSA early: The role of magnetic resonance imaging. J Neural Transm 2005; 112: 1625–34., , , .
MR imaging index for differentiation of progressive supranuclear palsy from Parkinson disease and the Parkinson variant of multiple system atrophy. Radiology 2008; 246: 214–21., , , , , , et al.
The role of spectroscopy in parkinsonism [Editorial; Comment]. Mov Disord 1998; 13: 2–4..
Systematic review of proton magnetic resonance spectroscopy of the striatum in parkinsonian syndromes. Eur J Neurol 2001; 8: 573–7., .
Proton MRS of the unilateral substantia nigra in the human brain at 4 tesla: Detection of high GABA concentrations. Magn Reson Med 2006; 55: 296–301., , , , , , et al.
Differentiation of multiple system atrophy from idiopathic Parkinson's disease using proton magnetic resonance spectroscopy. Ann Neurol 1995; 37: 204–10., , , , , , et al.
Usefulness of proton magnetic resonance spectroscopy in differentiating parkinsonian syndromes. Ital J Neurol Sci 1999; 20: 223–9., , , , , , et al.
Basal ganglia metabolite concentrations in idiopathic Parkinson's disease and multiple system atrophy measured by proton magnetic resonance spectroscopy. Eur J Neurol 2000; 7: 661–5., .
Multiple regional 1H-MR spectroscopy in multiple system atrophy: NAA/Cr reduction in pontine base as a valuable diagnostic marker. J Neurol Neurosurg Psychiatry 2004; 75: 103–09., , , , , , et al.
Proton magnetic resonance spectroscopic imaging in progressive supranuclear palsy, Parkinson's disease and corticobasal degeneration. Brain 1997; 120: 1541–52., , , , , , et al.
In vivo magnetic resonance spectroscopy of human fetal neural transplants. NMR Biomed 1999; 12: 221–36., , , , , , et al.
Huntington's disease. Lancet 2007; 20: 218–28..
Huntington's disease: Pathological mechanisms and therapeutic strategies. Cell Transplant 2007; 16: 301–12., , .
Using advances in neuroimaging to detect, understand, and monitor disease progression in Huntington's disease. Neurorx 2004; 1: 263–72., , .
Change in MRI striatal volumes as a biomarker in preclinical Huntington's disease. Brain Res Bull 2007; 72: 152–8..
Rate of caudate atrophy in presymptomatic and symptomatic stages of Huntington's disease. Mov Disord 2000; 15: 552–60., , , , , , et al.
Regional and progressive thinning of the cortical ribbon in Huntington's disease. Neurology 2002; 58: 695–701., , , , , , et al.
Prefrontal cortex volume reduction on MRI in preclinical Huntington's disease relates to visuomotor performance and CAG number. Parkinsonism Relat Disord 2008; 15: 213–9., , , , , , et al.
Cortical dysfunction in patients with Huntington's disease during working memory performance. Hum Brain Mapp 2009; 30: 327–39., , , , .
Variation of selective gray and white matter atrophy in Huntington's disease. Mov Disord 2007; 22: 1783–9., , , , , , et al.
Regional cortical thinning in preclinical Huntington disease and its relationship to cognition. Neurology 2005; 65: 745–7., , , , , .
Cerebral cortex and the clinical expression of Huntington's disease: Complexity and heterogeneity. Brain 2008; 131: 1057–68., , , , , , et al.
Evidence for impairment of energy metabolism in vivo in Huntington's disease using localized 1H NMR spectroscopy. Neurology 1993; 43: 2689–95., , , .
Energy metabolism defects in Huntington's disease and effects of coenzyme Q10. Ann Neurol 1997; 41: 160–5., , , .
Proton MRS in Huntington's disease [Letter; Comment]. Lancet 1994; 343: 1580., , , , .
1H NMR spectroscopy studies of Huntington's disease: Correlations with CAG repeat numbers. Neurology 1998; 50: 1357–65., , , , , , et al.
Proton magnetic resonance spectroscopy in Huntington's disease: Evidence in favour of the glutamate excitotoxic theory. Mov Disord 1996; 11: 167–73., , , , , , et al.
Re: Long-term fetal cell transplant in Huntington disease: Stayin' alive. Neurology 2008; 70: 815–6..
Prion diseases. J Neurovirol 2003; 9: 183–93., , .
The prion diseases. Brain Pathol 1998; 8: 499–513..
Inherited prion diseases. Adv Neurol 1993; 61: 155–65..
Recent advances in the pre-mortem diagnosis of Creutzfeldt–Jakob disease. J Clin Neurosci 2000; 7: 195–202., , , , , .
EEG in Creutzfeldt–Jakob disease. Clin Neurophysiol 2006; 117: 935–51., , .
Cerebrospinal fluid brain-derived proteins in the diagnosis of Alzheimer's disease and Creutzfeldt–Jakob disease. Neuropathol Appl Neurobiol 2002; 28: 427–40..
Prion infections of the brain. Neuroimaging Clin N Am 2008; 18: 183–91., .
Changes in N-acetylaspartate and myo-inositol detected in the cerebral cortex of hamsters with Creutzfeldt–Jakob disease. Magn Reson Imag 1998; 16: 963–8., , , .
Regional brain metabolite abnormalities in inherited prion disease and asymptomatic gene carriers demonstrated in vivo by quantitative proton magnetic resonance spectroscopy. Neuroradiology 2006; 48: 428–33., , , , , .
Systematic review of therapeutic interventions in human prion disease. Neurology 2008; 70: 1272–81., , , .
Amyotrophic lateral sclerosis. Lancet 2007; 369: 2031–41., .
Amyotrophic lateral sclerosis from bench to bedside. Semin Neurol 2008; 28: 205–11..
What has changed with riluzole? J Neurol 2000; 247: 19–22., , .
Diagnosis of amyotrophic lateral sclerosis. J Neurol Sci 1998; 160(Suppl 1): S6–24..
Measures and markers in amyotrophic lateral sclerosis. Neurorx 2004; 1: 273–83., , .
MRI in ALS: Corticospinal tract hyperintensity. Neurology 2004; 63: 596–7..
The diagnostic utility of FLAIR imaging in clinically verified amyotrophic lateral sclerosis. J Magn Reson Imag 2003; 17: 521–7., , , , , .
Corticospinal tract degeneration in amyotrophic lateral sclerosis: A diffusion tensor imaging and fibre tractography study. Ann Acad Med Singapore 2008; 37: 411–5., , , , , , et al.
Quantitative diffusion tensor imaging in amyotrophic lateral sclerosis. Neuroimage 2007; 34: 486–99., , , , .
Global brain atrophy and corticospinal tract alterations in ALS, as investigated by voxel-based morphometry of 3-D MRI. Amyotroph Lateral Scler Other Motor Neuron Disord 2005; 6: 213–20., , , , , , et al.
ALS corticospinal degeneration on DWI. Neurology 2004; 62: 1834., , .
Whole-brain and regional brain atrophy in amyotrophic lateral sclerosis. Am J Neuroradiol 2007; 28: 255–9., , , , , , et al.
Detection of cortical neuronal loss in motor neuron disease by proton magnetic resonance spectroscopic imaging in vivo. Neurology 1994; 44: 1933–8., , , .
ALS surrogate markers. MRS. Amyotroph Lateral Scler Other Motor Neuron Disord 2004; 5(Suppl 1): 111–4., .
Detection of cerebral degeneration in amyotrophic lateral sclerosis using high-field magnetic resonance spectroscopy. Arch Neurol 2006; 63: 1144–8., , , , .
Rapid improvement in cortical neuronal integrity in amyotrophic lateral sclerosis detected by proton magnetic resonance spectroscopic imaging. J Neurol 2006; 253: 1060–3., , , .
Recovery of N-acetylaspartate in corticomotor neurons of patients with ALS after riluzole therapy. Neuroreport 1998; 9: 1757–61., , , .
Research criteria for the diagnosis of Alzheimer's disease: Revising the NINCDS-ADRDA criteria. Lancet Neurol 2007; 6: 734–46., , , et al.
Diffusion tensor MRI of early upper motor neuron involvement in amyotrophic lateral sclerosis. Brain 2004; 127: 340–50., , , , , , et al.